| Status: Recommended with restrictions | ||
Brivaracetam (Briviact®) is recommended as an option for restricted use within NHS Wales Brivaracetam (Briviact®) should be restricted for use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. |
||
|
||
Medicine details |
||
| Medicine name | brivaracetam (Briviact®) | |
| Formulation | 10 mg, 25 mg, 50 mg, 75 mg, 100 mg film-coated tablets; 10 mg/ml oral solution; 10 mg/ml solution for injection/infusion | |
| Reference number | 4614 | |
| Indication | Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy |
|
| Company | UCB Pharma Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Licence extension for paediatric use | |
| Status | Recommended with restrictions | |
| Advice number | 1322 | |
| AWMSG meeting date | 12/07/2022 | |
| Date of issue | 19/07/2022 | |
| Further information This advice incorporates and replaces the AWMSG recommendation for brivaracetam (Briviact®) for restricted use in the treatment of patients with refractory epilepsy, in adults, adolescents and children from 4 years of age (Advice number 2318, originally published December 2018).
|
||